Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pan Afr Med J ; 40: 236, 2021.
Article in English | MEDLINE | ID: mdl-35178147

ABSTRACT

The rising burden of multiple myeloma in Kenya has not been met by a commensurate effort for control. Patients and practitioners struggle with unavailability and unaffordability of diagnostics, drugs and stem cell transplant leading to presentation at advanced stages and under-treatment with increased morbidities and mortality. A concerted effort among stakeholders is urgently needed to develop strategies for myeloma control. The scarcity of providers also carries grave consequences for Kenyan patients. The Academic Model Providing Access To Healthcare (AMPATH) multiple myeloma program organized the Inaugural Virtual Multiple Myeloma Congress to achieve both interactive specialist instruction and stakeholder engagement. Expert presenters and panellists from diverse disciplines were invited to offer in-depth presentations on myeloma care and case studies from panellists´ practice were used to contextualize learning points and form a basis for generating debate on the challenges facing providers and opportunities for care improvement. An audience of health professionals offering care to myeloma patients was invited. The underlying principle of recommendations developed during the congress was collaboration among in-country and international practitioners, researchers and policy experts from private and public sector. This partnership of stakeholders bears the potential of pooling scarce resources and for collective advocacy towards better patient care.


Subject(s)
Multiple Myeloma , Delivery of Health Care , Health Personnel , Humans , Kenya , Multiple Myeloma/therapy , Stakeholder Participation
2.
South Asian J Cancer ; 8(1): 60-64, 2019.
Article in English | MEDLINE | ID: mdl-30766858

ABSTRACT

INTRODUCTION: Plasma cells (PCs) have conventionally been counted on the bone marrow aspirate, and small focal involvement may be missed even on bone marrow biopsy sections. MATERIAL AND METHODS: We aimed to study the role of CD138, CD56, anti-κ, and anti-λ immunohistochemistry (IHC) to separate PC myeloma from reactive plasmacytosis and to study the utility of these in cases suspected as myelomas and lacking >10% PCs on bone marrow aspirate. The study comprised 35 diagnosed myelomas, 20 reactive plasmacytosis, and 19 M-band positive suspected myelomas. CD138 IHC was performed on all cases along with CD56, anti-κ, and anti-λ IHC. PCs were counted on CD138-immunostained sections by manual count and by image analysis. In addition, CD56 expression was correlated with clinical features in diagnosed myeloma group. RESULTS: In all cases, both manual counts and image analysis, PC counts were significantly higher on the CD138 stained sections than bone marrow aspirates. It was seen that the manual PC counts and image analysis counts were equivalent in diagnosed myeloma cases. CD56 expression was seen in ~62.85% diagnosed myeloma cases while it was negative in cases of reactive plasmacytosis. CD56 expression was significantly higher in patients with lytic lesions (78.26% vs. 21.74%). CD138, anti-κ, and anti-λ IHC also helped classify 11/19 (57.8%) cases correctly. CONCLUSION: The use of CD138 along with the light chain and CD56 IHC adds a high diagnostic value in myeloma patients and suspected myeloma cases. The PCs can be counted manually on the CD138-immunostained sections and correlate well with the counts obtained by image analysis.

3.
Blood Res ; 49(4): 241-5, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25548757

ABSTRACT

BACKGROUND: Aberrant myeloid antigen (MA) co-expression and high expression of CD34 antigen on the blasts of acute lymphoblastic leukemia (ALL) patients are independently reported to have a role in pathogenesis and prognosis. This study was conducted to determine whether these two parameters are related. METHODS: A total of 204 cases of ALL were included in an analysis of blast immunophenotypic data. CD34 expression was categorized as low when less than 50% of blasts were CD34-positive (CD34(low)) and as high when 50% or more were CD34-positive (CD34(high)). RESULTS: Of 204 cases of ALL, 163 and 41 were of B-cell origin (B-ALL) and T-cell origin (T-ALL), respectively. Of all cases, 132 (64.7%) showed co-expression of MA and among these, 101 (76.51%) were CD34(high), while the remaining 31 (23.48%) were CD34(low). Of 72 cases without MA co-expression, 25 (34.72%) were CD34(high) and 47 (67.25%) were CD34(low). Furthermore, of 163 cases of B-ALL, 111 showed co-expression of MA and 84 of these were CD34(high). Of 52 cases of B-ALL without MA expression, 22 were CD34(high). Among 41 cases of T-ALL, 21 co-expressed MA, 17 of which were CD34(high). Moreover, all 20 cases of T-ALL without co-expression of MA were CD34(low). These differences were statistically significant. CONCLUSION: We observed a strong correlation between aberrant MA expression and CD34(high) expression on the blasts of ALL. We hypothesize that these different patient subsets may represent unique prognostic characteristics.

4.
Indian J Hematol Blood Transfus ; 30(Suppl 1): 154-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25332566

ABSTRACT

Forty-five years old male, a known case of T cell acute lymphoblastic leukemia (ALL) on maintenance therapy presented with bilateral painless progressive diminution of vision. Evaluation revealed cytomegalovirus (CMV) retinitis with low CD4 counts. CMV retinitis is usually seen in HIV disease or in post allogenic stem cell transplant recipients. CMV retinitis occurring in ALL maintenance phase is very rare. The disease is aggressive and shows incomplete response to medical therapy.

5.
Anal Quant Cytol Histol ; 33(4): 236-44, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21980629

ABSTRACT

OBJECTIVE: To explore the utility of bone marrow (BM) angiogenesis in differentiating primary myelofibrosis (PMF) from secondary myelofibrosis (MF). STUDY DESIGN: CD34 immunostaining was performed on BM biopsies from 21 PMFs, 23 non-PMF myeloproliferative neoplasms (MPN) with associated MF, 20 secondary MF samples, and 10 nonfibrotic controls. Microvessel density (MVD) and microvessel surface area (MSA), along with blood and BM findings were compared between the groups. RESULTS: The post-MPN MF cases included chronic myeloid leukemia-MF and polycythemia vera-MF. Etiologies of secondary MF were metastatic carcinomas, non-MPN hematologic malignancies, tuberculosis, autoimmune MF, and osteopetrosis. Megakaryocytic clustering was the most frequent and intrasinusoidal hematopoiesis the most specific feature of PMF. Higher reticulin grade, collagenization, and osteomyelosclerosis were commoner in PMF. MVD and MSA were significantly increased in fibrotic marrows regardless of etiology. Although mean MVD as well as MSA were highest in PMF, extensive overlaps among groups and marked heterogeneity in the secondary MF group rendered them of limited utility in the differential diagnosis. CONCLUSION: Enhanced angiogenesis is not entirely specific for PMF. Overlaps with secondary MF limits its differential diagnostic utility. Pathogenetically, our findings suggest that enhanced angiogenesis is a secondary paraneoplastic stromal response shared by various unrelated conditions.


Subject(s)
Myeloproliferative Disorders/pathology , Neovascularization, Pathologic , Bone Marrow/blood supply , Bone Marrow/pathology , Diagnosis, Differential , Humans , Immunohistochemistry/methods , Microvessels/pathology , Myeloproliferative Disorders/diagnosis , Myeloproliferative Disorders/etiology , Primary Myelofibrosis/diagnosis , Primary Myelofibrosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...